| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 02/19/2004 | WO2004015085A2 Method and compositions relating to 5’-chimeric ribonucleic acids |
| 02/19/2004 | WO2004015084A2 Mutant e. coli appa phytase enzymes |
| 02/19/2004 | WO2004015083A2 Compositions and uses of motor protein-binding moieties |
| 02/19/2004 | WO2004015081A2 Methods for treating circadian rhythm phase disturbances |
| 02/19/2004 | WO2004015079A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 02/19/2004 | WO2004015075A2 Short interfering rnas having a hairpin structure containing a non-nucleotide loop |
| 02/19/2004 | WO2004015073A2 MP21S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE |
| 02/19/2004 | WO2004015072A2 Mrbs as modifiers of the rb pathway and methods of use |
| 02/19/2004 | WO2004015071A2 CSNK1GS AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE |
| 02/19/2004 | WO2004015070A2 Isolation and identification of t cells |
| 02/19/2004 | WO2004015068A2 Identification of seeds or plants using phenotypic markers |
| 02/19/2004 | WO2004015062A2 Methods and compositions relating to gene silencing |
| 02/19/2004 | WO2004015058A2 Nephritis treatment by gene therapy |
| 02/19/2004 | WO2004015057A2 Mucin-immunoglobulin fusion proteins |
| 02/19/2004 | WO2004014953A2 Anti-myelin associated glycoprotein (mag) antibodies |
| 02/19/2004 | WO2004014950A1 INTERFERON-α INDUCED GENE |
| 02/19/2004 | WO2004014936A2 Mixture of peptides from c and ns3 proteins of the hepatitis c virus and applications thereof |
| 02/19/2004 | WO2004014433A1 Inhibition of proliferation and infiltration of brain tumor cells caused by expression of ampa-type glutamate receptor subunit |
| 02/19/2004 | WO2004014420A1 Pharmaceutical compositions comprising an hiv envelope protein and cd4 |
| 02/19/2004 | WO2004014314A2 Methods and compositions concerning poxviruses and cancer |
| 02/19/2004 | WO2004014311A2 Nogo receptor antagonists |
| 02/19/2004 | WO2004014306A2 Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation |
| 02/19/2004 | WO2004014302A2 Mechanisms of myoblast transfer in treating heart failure |
| 02/19/2004 | WO2004014301A2 PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE |
| 02/19/2004 | WO2004014131A1 KNOCKIN NONHUMAN ANIMAL AND TISSUE-SPECIFIC MnSOD-KNOCKOUT NONHUMAN ANIMAL |
| 02/19/2004 | WO2004014128A1 Method of elevating ggt activity of plant, plant with elevated ggt activity and method of constructing the same |
| 02/19/2004 | WO2004007726A3 Brachyspira hyodysenteriae vaccine |
| 02/19/2004 | WO2004007539A3 Hsp70 from arthrobacter |
| 02/19/2004 | WO2004003133A8 Pain signaling molecules |
| 02/19/2004 | WO2004001024A3 Genetically engineered keratinocytes expressing at least one growth factor and/or activated egf receptor, skin equivalent comprising said keratinocytes and toxicity assay using said keratinocytes |
| 02/19/2004 | WO2003106667A3 Regulation of human subtilase-like serine protease |
| 02/19/2004 | WO2003106490B1 A fusion protein comprising a cellulose binding domain |
| 02/19/2004 | WO2003103719A3 Method for triggering apoptosis in cells by increasing the level of c1d and inhibiting the degradation of the same |
| 02/19/2004 | WO2003103706A3 Immunogenic compositions comprising a xenogenic prostate protein p501s |
| 02/19/2004 | WO2003102584A3 Semaphorin-like proteins and methods of using same |
| 02/19/2004 | WO2003102137A3 Compositions and methods relating to lung specific genes and proteins |
| 02/19/2004 | WO2003102129A3 Photorhabdus luminescens mcf toxin genes and uses thereof |
| 02/19/2004 | WO2003100060A3 Muc-1 antigen with reduced number of vntr repeat units |
| 02/19/2004 | WO2003099193A3 Vaccines |
| 02/19/2004 | WO2003097852A3 Assay for identifying inhibitors of fc gamma riii signaling |
| 02/19/2004 | WO2003097834A3 A method for in vitro molecular evolution of protein function |
| 02/19/2004 | WO2003097808A9 Automated system for isolating, amplyifying and detecting a target nucleic acid sequence |
| 02/19/2004 | WO2003097797A3 Methods of adenovirus purification |
| 02/19/2004 | WO2003095647A3 CHIMERIC snRNA MOLECULES CARRYING ANTISENSE SEQUENCES AGAINST THE SPLICE JUNCTIONS OF THE DYSTROPHIN GENE AND THEIR THERAPEUTIC APPLICATIONS |
| 02/19/2004 | WO2003095605A3 A chimeric reverse transcriptase and methods for identifying telomerase inhibitors |
| 02/19/2004 | WO2003093428A3 Gene targeting using replicating dna molecules |
| 02/19/2004 | WO2003091392A3 Polymer-coated substrates for immobilization of biomolecules and cells |
| 02/19/2004 | WO2003088979A3 Oligonucleotides from sequences coding for the surface component of envelope proteins of primate t-cell leukaemia/lymphoma viruses (ptlv) and uses thereof |
| 02/19/2004 | WO2003087318A3 Truncated 24 kda basic fibroblast growth factor |
| 02/19/2004 | WO2003085124A8 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 02/19/2004 | WO2003084986A3 Novel purified polypeptides involved in cellular metabolism |
| 02/19/2004 | WO2003080640B1 Lymphatic and blood endothelial cell genes |
| 02/19/2004 | WO2003078658A3 Methods for diagnosing and treating schizophrenia |
| 02/19/2004 | WO2003076595A3 Production of insulin and insulin-like proteins in plants |
| 02/19/2004 | WO2003074734A3 Methods for detecting genome-wide sequence variations associated with a phenotype |
| 02/19/2004 | WO2003072803A3 Nanostructures containing antibody assembly units |
| 02/19/2004 | WO2003070904A3 Human rnase iii and compositions and uses thereof |
| 02/19/2004 | WO2003070188A3 Method of treating trx mediated diseases |
| 02/19/2004 | WO2003065046A3 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor |
| 02/19/2004 | WO2003064605A3 Crude biological derivatives competent for nucleic acid detection |
| 02/19/2004 | WO2003064602A3 Methods of modulating cold sensory perception |
| 02/19/2004 | WO2003062379A3 Molecules for disease detection and treatment |
| 02/19/2004 | WO2003060119A3 Method for the quantification of in vivo nucleic acid levels |
| 02/19/2004 | WO2003060109A3 Human subtilisin/kexin-like convertase |
| 02/19/2004 | WO2003060092A3 Modified fatty acid hydroxylase protein and genes |
| 02/19/2004 | WO2003054510A3 Method and device for removal of organic molecules |
| 02/19/2004 | WO2003054172A3 Glutamine-auxothrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium |
| 02/19/2004 | WO2003054016A3 Method for cloning of variable domain sequences |
| 02/19/2004 | WO2003053136A3 Triple transgenic mouse model of alzheimer's disease |
| 02/19/2004 | WO2003052051A3 Adeno-associated virus (aav) serotype 8 sequences |
| 02/19/2004 | WO2003050265A3 Compositions and methods for normalizing assays |
| 02/19/2004 | WO2003048780A3 Uses of aldose-1-epimerase (mutarotase) for diagnosis and therapy of inflammatory diseases and sepsis |
| 02/19/2004 | WO2003048384A3 Methods of identifying genetic risk for and evaluating treatment of alzheimer's disease by determing single nucleotide polymorphisms |
| 02/19/2004 | WO2003048193A3 GIPs, A FAMILY OF POLYPEPTIDES WITH TRANSCRIPTION FACTOR ACTIVITY THAT INTERACT WITH GOODPASTURE ANTIGEN BINDING PROTEIN |
| 02/19/2004 | WO2003046149A3 Methods of using improved polymerases |
| 02/19/2004 | WO2003042379A3 A new disintegrin and metalloproteinase with thrombospondin type i repeats polynucleotide and its encoded polypeptide |
| 02/19/2004 | WO2003042364A3 Identifying and controlling the growth of estrogen-responsive cells |
| 02/19/2004 | WO2003040306A3 Compositions from the grasses lolium perenne and festuca arundinacea |
| 02/19/2004 | WO2003040167A3 Peptides which deliver antisense oligonucleotides and downregulate protein expression in cells |
| 02/19/2004 | WO2003038724A3 Methods and apparatus for protein sequence analysis |
| 02/19/2004 | WO2003034028A3 Methods for identifying and using modulators of estrogen related receptor gamma |
| 02/19/2004 | WO2003032925A3 Glycosulfopeptide inhibitors and methods of use thereof |
| 02/19/2004 | WO2003029454A3 Non-human animal model for analysis of the origin and therapy of organ fibrosis |
| 02/19/2004 | WO2003027291A3 Hdv nucleic acid molecules, fragments and applications thereof |
| 02/19/2004 | WO2003023061A3 Reading, detection or quantification method, hybrids or complexes used in said method and the biochip using same |
| 02/19/2004 | WO2003018770A3 Amplified oncogenes and their involvement in cancer |
| 02/19/2004 | WO2003016564A3 Use of associations between at least one nucleic sequence polymorphism of the sh2 gene and at least one seed quality characteristic in plant selection methods |
| 02/19/2004 | WO2003016482A3 Methyltransferase genes and uses thereof |
| 02/19/2004 | WO2003014731A3 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |
| 02/19/2004 | WO2003010294A3 Genes involved in the biosynthesis of isopentenyl diphosphate in hevea brasiliensis latex |
| 02/19/2004 | WO2003008537A9 Epitope sequences |
| 02/19/2004 | WO2003000719A8 Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same |
| 02/19/2004 | WO2003000113A9 Compositions and methods for the diagnosis and treatment of tumor |
| 02/19/2004 | WO2002092835A3 Isolated human g protein-coupled receptor |
| 02/19/2004 | WO2002090514A8 Epidermal growth factor receptorantisense oligonucleotides |
| 02/19/2004 | WO2002088325A3 Vector system for selection of genes encoding secreted proteins and membrane-bound proteins |
| 02/19/2004 | WO2002088185A3 Pan-specific monoclonal antibody |
| 02/19/2004 | WO2002086101A3 Core-glycosylated hcv envelope proteins |
| 02/19/2004 | WO2002086100A3 Expression of core-glycosylated hcv envelope proteins in yeast |
| 02/19/2004 | WO2002083867A3 Ires enabled gene trapping in plants |